Pembrolizumab + Paclitaxel + Bevacizumab
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Triple-Negative Breast Cancer
Conditions
Recurrent Triple-Negative Breast Cancer
Trial Timeline
Jun 24, 2025 → Sep 1, 2028
NCT ID
NCT06976944About Pembrolizumab + Paclitaxel + Bevacizumab
Pembrolizumab + Paclitaxel + Bevacizumab is a phase 2 stage product being developed by Merck for Recurrent Triple-Negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06976944. Target conditions include Recurrent Triple-Negative Breast Cancer.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Triple-Negative Breast Cancer were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06976944 | Phase 2 | Recruiting |
Competing Products
20 competing products in Recurrent Triple-Negative Breast Cancer